Depression occurs in up to 21% of IBD patients and is associated with increased healthcare costs. Antidepressants (AD), used by nearly 29% of IBD patients, target stress and depression, functional intestinal and somatic symptoms. IBD-related perception of disease, healthcare utilization, quality of life and outcomes are associated with racial and socio-economic disparities. Determining clinical and epidemiological predictors of antidepressant use in IBD will help identify vulnerable populations and maximize healthcare delivery.